Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50 Day Moving Average – What’s Next?

Pulmatrix, Inc. (NASDAQ:PULM)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.71 and traded as low as $2.44. Pulmatrix shares last traded at $2.43, with a volume of 5,040 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Pulmatrix Stock Down 1.2%

The company’s fifty day moving average price is $2.71 and its 200-day moving average price is $4.07.

Hedge Funds Weigh In On Pulmatrix

A number of large investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. grew its position in Pulmatrix by 15.7% in the 2nd quarter. SBI Securities Co. Ltd. now owns 60,565 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 8,208 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Pulmatrix during the third quarter valued at $52,000. Finally, DRW Securities LLC bought a new position in shares of Pulmatrix in the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).